title: [The effect of oral contraceptives on the orthostatic diameter of lower limb major veins and its correction].
abstract: The study assessed the effect of combined oral contraceptives (COCs) on the lower limb major vein diameter during orthostasis and the possibility of its medical correction in 214 women aged 17-42 with chronic venous insufficiency (CVI), including 37 women with CEAP class C0, 76 - with class C1 and 101 - with class C2. Venous diameter was measured by duplex scanning; its increment between evening and morning measurements was calculated in 3 groups. In the first group (n=68) venous diameter was measured before COC indication and after 2 months of COC use. In this group the second assessment revealed significant increase in venous diameter among women with CVI classes C1 and C1. The second group (n=69) received COCs for at least 6 months; then COC was withdrawn and Flebodia 600 was indicated. In this group venous scanning was fulfilled during COC use and after 2 months of its withdrawal and Flebodia 600 indication. Statistically significant decrease of orthostatic venous diameter was demonstrated for all scanned veins, evidencing diosmine-induced enhanced venous tone. The third group (n=77) did not interrupted COC intake and received Flebodia 600 concurrently. In this group venous measurements were fulfilled before and after 2 months of Flebodia 600 intake. Significant, though not ubiquitous decrease of venous diameter was registered in this group.
  
  
  CONCLUSIONS
  Phlebopathic effect of COCs was demonstrated in women with CVI, CEAP classes 0-1-2, as well as safety and efficiency of Flebodia 600. The results prove the feasibility of Flebodia 600 indication for this population in case of COC intake.
authors.forename: Iu T
authors.initials: IuT
authors.lastname: Tsukanov
authors.forename: A Iu
authors.initials: AIu
authors.lastname: Tsukanov
authors.forename: V N
authors.initials: VN
authors.lastname: Bazhenov
mesh_terms: D000293:Adolescent; D000328:Adult; D003278:Contraceptives, Oral, Hormonal / Q000009:adverse effects*; D004145:Diosmin / Q000494:pharmacology* / Q000627:therapeutic use*; D004244:Dizziness; D004730:Endothelium, Vascular / Q000000981:diagnostic imaging / Q000187:drug effects; D005260:Female; D005268:Femoral Vein / Q000000981:diagnostic imaging / Q000187:drug effects; D006801:Humans; D012501:Saphenous Vein / Q000000981:diagnostic imaging / Q000187:drug effects; D018616:Ultrasonography, Doppler, Duplex; D014689:Venous Insufficiency / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000517:prevention & control*; D020246:Venous Thrombosis / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000517:prevention & control*; D055815:Young Adult
chemical_list: D003278:Contraceptives, Oral, Hormonal; D004145:Diosmin